ArticleThe Journal of clinical investigation2004
Critical roles of TRAIL in hepatic cell death and hepatic inflammation.
Article in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 157 citations in OpenAlex.
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.British journal of cancer · 2010Trial
- Large-Scale Plasma Proteomics Reveals Preclinical Biomarkers of Incident Severe Liver Disease.Proteomics. Clinical applications · 2026Article
- Transplantation of chemically induced liver progenitors in Nagase analbuminemic rats under liver regenerative stimulus.Regenerative therapy · 2025Article
- Advancing Systemic Therapy in Chondrosarcoma: New Horizons.Oncology and therapy · 2025Article
- RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives.International journal of molecular sciences · 2024Review
- Review
- LIGHT Amplification by NF-Mediators of inflammation · 2023Article
- Article
- Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure.Journal of molecular medicine (Berlin, Germany) · 2019Article
- Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice.PloS one · 2019Article
- CEACAM1 in Liver Injury, Metabolic and Immune Regulation.International journal of molecular sciences · 2018Review
- Combined application of Embelin and tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and invasion in osteosarcoma cells via caspase-induced apoptosis.Oncology letters · 2018Article
- Cancer preventive effect of recombinant TRAIL by ablation of oncogenic inflammation in colitis-associated cancer rather than anticancer effect.Oncotarget · 2018Article
- Hepatoprotective Effect of San-Cao Granule on Con A-Induced Liver Injury in Mice and Mechanisms of Action Exploration.Frontiers in pharmacology · 2018Article
- Analyzing the innate immunity of NIH hairless mice and the impact of gut microbial polymorphisms onOncotarget · 2017Article
- RIPK1 protects hepatocytes from death in Fas-induced hepatitis.Scientific reports · 2017Article
- Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.World journal of gastroenterology · 2017Article
- Crosstalk of liver immune cells and cell death mechanisms in different murine models of liver injury and its clinical relevance.Hepatobiliary & pancreatic diseases international : HBPD INT · 2017Review
- The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells.Scientific reports · 2017Article
- Protective Effect ofFrontiers in microbiology · 2017Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis of tumor cells but not most normal cells. Its role in hepatic cell death and hepatic diseases is not clear. In vitro studies suggest that murine hepatocytes are not sensitive to TRAIL-induced apoptosis, indicating that TRAIL may not mediate hepatic cell death. Using two experimental models of hepatitis, we found that hepatic cell death in vivo was dramatically reduced in TRAIL-deficient mice and mice treated with a blocking TRAIL receptor. Although both TRAIL and its death receptor 5 were constitutively expressed in the liver, TRAIL expression by immune cells alone was sufficient to restore the sensitivity of TRAIL-deficient mice to hepatitis. Thus, TRAIL plays a crucial role in hepatic cell death and hepatic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.